Schedule of Deferred Tax Assets |
|
|
As of December 31, |
|
|
2016 |
|
2015 |
Deferred tax assets: |
|
|
|
|
|
|
|
|
Net operating loss carryforwards |
|
$ |
66,150,646 |
|
|
$ |
60,129,827 |
|
R&D credit carryforwards |
|
|
9,729,673 |
|
|
|
9,465,900 |
|
Stock compensation |
|
|
1,368,458 |
|
|
|
1,898,394 |
|
Intangibles |
|
|
1,720,761 |
|
|
|
1,921,934 |
|
Temporary differences |
|
|
132,475 |
|
|
|
801,002 |
|
Deferred tax assets before valuation allowance |
|
|
79,102,014 |
|
|
|
74,217,057 |
|
Valuation allowance |
|
|
(79,102,014 |
) |
|
|
(74,217,057 |
) |
Net deferred tax assets |
|
$ |
— |
|
|
$ |
— |
|
|
Schedule of NOL and Credit Carryforward Amounts |
|
|
|
|
As of December 31, 2016 |
Generated |
|
Expiration |
|
U.S. Net Operating Loss Carryforwards
|
|
U.S. R&D Credit Carryforwards
|
|
1998 |
|
|
|
2018 |
|
|
$ |
17,142,781 |
|
|
$ |
1,173,387 |
|
|
1999 |
|
|
|
2019 |
|
|
|
— |
|
|
|
130,359 |
|
|
2000 |
|
|
|
2020 |
|
|
|
— |
|
|
|
71,713 |
|
|
2001 |
|
|
|
2021 |
|
|
|
— |
|
|
|
39,128 |
|
|
2002 |
|
|
|
2022 |
|
|
|
1,282,447 |
|
|
|
5,350 |
|
|
2003 |
|
|
|
2023 |
|
|
|
337,714 |
|
|
|
2,905 |
|
|
2004 |
|
|
|
2024 |
|
|
|
1,237,146 |
|
|
|
22,861 |
|
|
2005 |
|
|
|
2025 |
|
|
|
2,999,083 |
|
|
|
218,332 |
|
|
2006 |
|
|
|
2026 |
|
|
|
3,049,735 |
|
|
|
365,541 |
|
|
2007 |
|
|
|
2027 |
|
|
|
2,842,078 |
|
|
|
342,898 |
|
|
2008 |
|
|
|
2028 |
|
|
|
2,777,503 |
|
|
|
531,539 |
|
|
2009 |
|
|
|
2029 |
|
|
|
13,727,950 |
|
|
|
596,843 |
|
|
2010 |
|
|
|
2030 |
|
|
|
5,397,680 |
|
|
|
1,094,449 |
|
|
2011 |
|
|
|
2031 |
|
|
|
1,875,665 |
|
|
|
1,950,744 |
|
|
2012 |
|
|
|
2032 |
|
|
|
28,406,659 |
|
|
|
468,008 |
|
|
2013 |
|
|
|
2033 |
|
|
|
37,450,522 |
|
|
|
681,772 |
|
|
2014 |
|
|
|
2034 |
|
|
|
34,088,874 |
|
|
|
816,116 |
|
|
2015 |
|
|
|
2035 |
|
|
|
25,073,846 |
|
|
|
492,732 |
|
|
2016 |
|
|
|
2036 |
|
|
|
15,581,209 |
|
|
|
358,404 |
|
|
Total carryforwards |
|
|
|
|
|
|
$ |
193,270,891 |
|
|
$ |
9,363,081 |
|
|
Schedule of Effective Income Tax Rate Reconciliation |
|
|
Years Ended December 31, |
|
|
2016 |
|
2015 |
|
2014 |
|
|
Amount |
|
% |
|
Amount |
|
% |
|
Amount |
|
% |
Benefit at statutory rate |
|
$ |
(4,864,851 |
) |
|
|
(34.0 |
)% |
|
$ |
(9,777,786 |
) |
|
|
(34.0 |
)% |
|
$ |
(12,147,068 |
) |
|
|
(34.0 |
)% |
Adjustments to valuation allowance |
|
|
4,838,082 |
|
|
|
33.8 |
% |
|
|
9,728,667 |
|
|
|
33.8 |
% |
|
|
12,925,380 |
|
|
|
36.2 |
% |
Adjustments to R&D credit carryforwards |
|
|
(239,049 |
) |
|
|
(1.6 |
)% |
|
|
(612,087 |
) |
|
|
(2.1 |
)% |
|
|
(340,886 |
) |
|
|
(1.0 |
)% |
Disqualified debt interest |
|
|
188,060 |
|
|
|
1.3 |
% |
|
|
438,007 |
|
|
|
1.5 |
% |
|
|
— |
|
|
|
0.0 |
% |
Permanent items and other |
|
|
77,758 |
|
|
|
0.5 |
% |
|
|
(212,852 |
) |
|
|
(0.7 |
)% |
|
|
(437,426 |
) |
|
|
(1.2 |
)% |
Benefit per financial statements |
|
$ |
— |
|
|
|
|
|
|
$ |
(436,051 |
) |
|
|
|
|
|
$ |
— |
|
|
|
|
|
|